TALPHERA, INC. (TLPH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_979677.htm EXHIBIT 10.1 ex_979677.htm Exhibit 10.1 AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN Originally Adopted by the Board of Directors: April 16, 2020 Originally Approved by the Stockholders: June 16, 2020 Amendment and Restatement Approved by the Board of D

Event · Shareholder vote
Original reporting
Published Jun 23, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$TLPH
Neutral
medium confidence
Mentioned
$TLPH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TLPHNeutralLow
01

Why it matters

The disclosed items are governance and compensation-related; without the specific personnel changes and compensation numbers, the excerpt does not provide a clear fundamental catalyst.

02

Market read

Primarily informs corporate governance/compensation expectations; actionable trading impact is likely limited unless the omitted exhibit sections contain material leadership or pay changes.

03

What to watch

Traders should verify the specific director/officer changes and the exact compensatory terms in the exhibits (not shown in the excerpt), since those can drive sentiment and forward-looking expectations.

Relevance 6/10Novelty 3/10Timing: Filed after-hours/late day (2026-06-23 16:27 ET) for an 8-K governance/compensation update.

Background

The article is an SEC EDGAR 8-K filing for Talphera, Inc. covering Item 5.02 (director/officer changes and compensatory arrangements) and Item 5.07 (vote submission). The excerpt includes extensive text from an amended and restated equity incentive plan.

Company-level read

Ticker impact

$TLPHNeutralMedium confidence
Context

Talphera filed an 8-K for director/officer departures and elections plus compensatory arrangements under Item 5.02.

Expected impact

Likely limited immediate price impact unless the omitted exhibits specify material pay changes or leadership turnover details.

Evidence & confidence

The filing type (8-K Item 5.02) is primary and time-stamped, but the provided body excerpt is largely plan boilerplate and does not include the specific personnel changes or compensation terms.

Market effects

Minimal—no sector-wide regulatory, clinical, or macro datapoints disclosed.

None indicated.

None indicated.

Counterpoint

If the missing exhibit details include a meaningful executive departure or unusually large equity/option grants, the market reaction could be larger than typical for routine plan amendments.

Key entities

  • Talphera, Inc.

    Subject of the 8-K; disclosed director/officer changes and compensatory arrangements plus equity incentive plan amendment/restatement details.

Related articles

$TLPHMed

Talphera (TLPH) Q3 2026 Earnings Call Transcript

Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.

$TLPHMed

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMedAI 8/10

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

$TLPHMed

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi